Telix Pharmaceuticals Reports 56% Revenue Surge and Advances Oncology Pipeline

Key Facts

1Telix reported FY2025 revenue of $804 million, representing a 56% year-over-year increase.

2The products Illuccix and Gozellix contributed $622 million to the total revenue.

3Lead asset TLX591-Tx is advancing in Phase 3 trials for metastatic castration-resistant prostate cancer (mCRPC).

Telix Pharmaceuticals reported robust financial results for fiscal year 2025, with total revenue reaching $804 million, a 56% increase year-over-year. The company's strong performance was primarily driven by its key products, Illuccix and Gozellix, which together contributed $622 million to the total revenue. In addition to financial growth, Telix is making significant clinical strides with its lead asset, TLX591-Tx, currently advancing in Phase 3 trials. This treatment targets metastatic castration-resistant prostate cancer (mCRPC), positioning the company as a leader in the radio antibody-drug conjugate space. Analysts have maintained a 'Buy' rating on the stock, citing the combination of rapid revenue growth and a maturing late-stage clinical pipeline. The expansion of its oncology portfolio underscores Telix's commitment to delivering precision medicine solutions for high-demand cancer treatments.